投资5.56亿！诺和诺德扩展中国市场，肥胖新药潜力超230亿

和讯网04-11

和讯为您带来近期券商看点，供您参考：诺和诺德新药amycretin片临床试验申请获受理4月10日，中国国家药监局药品审评中心官网公示，诺和诺德1类新药amycretin片的临床试验申请获得受理。该药品是一款口服GLP-1受体和胰淀素受体的长效共激动剂，正在开发皮下注射和口服两种剂型，目前拟开发适应症为肥胖。最新临床试验结果显示，患者在接受治疗12周后体重下降幅度达13.1%，显示出在减重方面的巨大...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2426409014?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-04-11 11:54","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2426409014","market":"us","top_or_hot":-1,"title":"投资5.56亿！诺和诺德扩展中国市场，肥胖新药潜力超230亿","media":"和讯网","content":"<div>\n<p>和讯为您带来近期券商看点，供您参考：诺和诺德新药amycretin片临床试验申请获受理4月10日，中国国家药监局药品审评中心官网公示，诺和诺德1类新药amycretin片的临床试验申请获得受理。该药品是一款口服GLP-1受体和胰淀素受体的长效共激动剂，正在开发皮下注射和口服两种剂型，目前拟开发适应症为肥胖。最新临床试验结果显示，患者在接受治疗12周后体重下降幅度达13.1%，显示出在减重方面的巨大...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041111550287654054&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>投资5.56亿！诺和诺德扩展中国市场，肥胖新药潜力超230亿</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n投资5.56亿！诺和诺德扩展中国市场，肥胖新药潜力超230亿\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-11 11:54 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041111550287654054&s=b><strong>和讯网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>和讯为您带来近期券商看点，供您参考：诺和诺德新药amycretin片临床试验申请获受理4月10日，中国国家药监局药品审评中心官网公示，诺和诺德1类新药amycretin片的临床试验申请获得受理。该药品是一款口服GLP-1受体和胰淀素受体的长效共激动剂，正在开发皮下注射和口服两种剂型，目前拟开发适应症为肥胖。最新临床试验结果显示，患者在接受治疗12周后体重下降幅度达13.1%，显示出在减重方面的巨大...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041111550287654054&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041111550287654054&s=b","article_id":"2426409014","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024041111550287654054&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2426409014","pubTimestamp":1712807699,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"诺和诺德加大对中国市场投入当地时间4月9日，诺和诺德宣布将投资约5.56亿美元用于升级和扩建其在中国天津的生产基地。该投资旨在提升公司在中国的生产能力，满足市场对创新药物的需求，并采用创新技术提升生产效率和产品质量。中国减肥药市场潜力巨大机构预测，未来6年中国的糖尿病及减肥药物市场规模将超过230亿美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4007":"制药","BK4532":"文艺复兴科技持仓","BK4585":"ETF&股票定投概念","NVO":"诺和诺德","BK4588":"碎股"},"translate_title":"Invest 556 million! Novo Nordisk expands the Chinese market, and the potential of new obesity drugs exceeds 23 billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"和讯为您带来近期券商看点，供您参考：诺和诺德新药amycretin片临床试验申请获受理4月10日，中国国家药监局药品审评中心官网公示，诺和诺德1类新药amycretin片的临床试验申请获得受理。该药品是一款口服GLP-1受体和胰淀素受体的长效共激动剂，正在开发皮下注射和口服两种剂型，目前拟开发适应症为肥胖。最新临床试验结果显示，患者在接受治疗12周后体重下降幅度达13.1%，显示出在减重方面的巨大潜力。诺和诺德加大对中国市场投入当地时间4月9日，诺和诺德宣布将投资约5.56亿美元用于升级和扩建其在中国天津的生产基地。该投资旨在提升公司在中国的生产能力，满足市场对创新药物的需求，并采用创新技术提升生产效率和产品质量。中国减肥药市场潜力巨大机构预测，未来6年中国的糖尿病及减肥药物市场规模将超过230亿美元。分析师预测，中国的GLP-1类药物市场年增长率将超过全球平均水平。随着专利到期，新药的开发对于维持公司市场地位和盈利能力至关重要。和讯自选股写手风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保证和承诺。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2426409014"}